Evidence map›Paper›PMID 39968132›Full record

ArticleHeliyon2025

LINC00870 promotes imatinib resistance in gastrointestinal stromal tumor via inhibiting PIGR glycosylation modifications.

Yuan Li, Zhiqiang Dai, Zewei Cheng, Junyi He, Yirui Yin, Xinyou Liu, Jiwei Zhang, Guohua Hu, Yueda Chen, Xuefei Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuan LiCentral Laboratory, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.
Zhiqiang DaiDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.
Zewei ChengShanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Junyi HeDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.
Yirui YinDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.
Xinyou LiuDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.
Jiwei ZhangShanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Guohua HuDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.
Yueda ChenDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.
Xuefei WangDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.
Yebo ShaoDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imatinib is the first-line targeted therapy for gastrointestinal stromal tumor (GIST), but resistance frequently occurs during treatment, limiting its efficacy and clinical application. We performed high-throughput sequencing of tissue specimens from imatinib-resistant GIST patients, and identified significantly high expression of polymeric immunoglobulin receptor (PIGR) in imatinib-resistant cell lines. Further investigation revealed that PIGR binds specifically to LINC00870. The findings from

Indexed as

Gastrointestinal stromal tumorGlycosylation modificationsImatinibLINC00870Polymeric immunoglobulin receptor

Identifiers

PMID39968132
PMCPMC11834037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.